Novo Nordisk: files for label change of fast-acting insulin
(CercleFinance.com) - Novo Nordisk said that it has filed for a label update for its fast-acting insulin Fiasp with European and US heatlh regulators, seeking approval for use in children and teenagers.
The Danish firm has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the drug's use as a new mealtime insulin for children and teenagers with type 1 diabetes, it said.
Fiasp is currently indicated for the treatment of type 1 and type 2 diabetes in adults only.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Danish firm has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the drug's use as a new mealtime insulin for children and teenagers with type 1 diabetes, it said.
Fiasp is currently indicated for the treatment of type 1 and type 2 diabetes in adults only.
Copyright (c) 2019 CercleFinance.com. All rights reserved.